{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T11:30:13Z","timestamp":1791199813379,"version":"4.2.0"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Toxicology Letters"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1016\/j.toxlet.2016.10.017","type":"journal-article","created":{"date-parts":[[2016,11,1]],"date-time":"2016-11-01T21:16:21Z","timestamp":1478034981000},"page":"23-29","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Rosuvastatin safety: An experimental study of myotoxic effects and mitochondrial alterations in rats"],"prefix":"10.1016","volume":"265","author":[{"given":"Samar O.","family":"El-Ganainy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"El-Mallah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dina","family":"Abdallah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud M.","family":"Khattab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud M.","family":"Mohy El-Din","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aiman S.","family":"El-Khatib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.toxlet.2016.10.017_bib0005","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1517\/14740338.2011.540568","article-title":"Statin-induced myopathy: a review and update","volume":"10","author":"Abd","year":"2011","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.toxlet.2016.10.017_bib0010","first-page":"1841","article-title":"The AKT\/mTOR signaling pathway plays a key role in statin-induced myotoxicity","volume":"1853","author":"Bonifacio","year":"2015","journal-title":"BBA-Mol. Cell Res."},{"key":"10.1016\/j.toxlet.2016.10.017_bib0015","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1152\/japplphysiol.00107.2011","article-title":"Atorvastatin treatment reduces exercise capacities in rats: involvement of mitochondrial impairments and oxidative stress","volume":"111","author":"Bouitbir","year":"2011","journal-title":"J. Appl. Physiol."},{"key":"10.1016\/j.toxlet.2016.10.017_bib0020","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/0003-2697(76)90527-3","article-title":"A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding","volume":"72","author":"Bradford","year":"1976","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.toxlet.2016.10.017_bib0025","doi-asserted-by":"crossref","first-page":"171","DOI":"10.2165\/11319380-000000000-00000","article-title":"Risk factors and drug interactions predisposing to statin-induced myopathy","volume":"33","author":"Chatzizisis","year":"2010","journal-title":"Drug Saf."},{"key":"10.1016\/j.toxlet.2016.10.017_bib0030","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/j.metabol.2009.03.006","article-title":"Adding exercise training to rosuvastatin treatment: influence on serum lipids and biomarkers of muscle and liver damage","volume":"58","author":"Coen","year":"2009","journal-title":"Metabolism"},{"key":"10.1016\/j.toxlet.2016.10.017_bib0035","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1046\/j.1365-2125.1996.04178.x","article-title":"Lipid-lowering drugs and mitochondrial function: effects of HMG-CoA reductase inhibitors on serum ubiquinone and blood lactate\/pyruvate ratio","volume":"42","author":"De Pinieux","year":"1996","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.toxlet.2016.10.017_bib0040","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1242\/jeb.017640","article-title":"Scaling of muscle architecture and fiber types in the rat hindlimb","volume":"211","author":"Eng","year":"2008","journal-title":"J. Exp. Biol."},{"key":"10.1016\/j.toxlet.2016.10.017_bib0045","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1124\/pr.111.004994","article-title":"Pharmacological actions of statins: a critical appraisal in the management of cancer","volume":"64","author":"Gazzerro","year":"2012","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.toxlet.2016.10.017_bib0050","doi-asserted-by":"crossref","first-page":"e42866","DOI":"10.1371\/journal.pone.0042866","article-title":"A survey of the FDA's AERS database regarding muscle and tendon adverse events linked to the statin drug class","volume":"7","author":"Hoffman","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.toxlet.2016.10.017_bib0055","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/S0893-133X(02)00374-3","article-title":"Evaluation of antidepressant-related behavioral responses in mice lacking the serotonin transporter","volume":"27","author":"Holmes","year":"2002","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.toxlet.2016.10.017_bib0060","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1007\/s00018-006-6235-z","article-title":"Toxicity of statins on rat skeletal muscle mitochondria","volume":"63","author":"Kaufmann","year":"2006","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.toxlet.2016.10.017_bib0065","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1161\/CIRCRESAHA.109.203596","article-title":"Human skeletal muscle drug transporters determine local exposure and toxicity of statins","volume":"106","author":"Knauer","year":"2010","journal-title":"Circ. Res."},{"key":"10.1016\/j.toxlet.2016.10.017_bib0070","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/j.lfs.2008.02.019","article-title":"Association between risk of myopathy and cholesterol-lowering effect: a comparison of all statins","volume":"82","author":"Kobayashi","year":"2008","journal-title":"Life Sci."},{"key":"10.1016\/j.toxlet.2016.10.017_bib0075","doi-asserted-by":"crossref","first-page":"11","DOI":"10.2165\/13168600-000000000-00000","article-title":"Rosuvastatin-associated adverse effects and drug\u2013drug interactions in the clinical setting of dyslipidemia","volume":"10","author":"Kostapanos","year":"2010","journal-title":"Am. J. Cardiovasc. Drugs"},{"key":"10.1016\/j.toxlet.2016.10.017_bib0080","doi-asserted-by":"crossref","first-page":"S52","DOI":"10.1016\/j.amjcard.2005.12.010","article-title":"Statin safety: a systematic review","volume":"97","author":"Law","year":"2006","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.toxlet.2016.10.017_bib0085","doi-asserted-by":"crossref","first-page":"e154","DOI":"10.1016\/j.atherosclerosis.2006.12.001","article-title":"Efficacy and safety of rosuvastatin 40mg versus atorvastatin 80mg in high-risk patients with hypercholesterolemia: results of the POLARIS study","volume":"194","author":"Leiter","year":"2007","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.toxlet.2016.10.017_bib0090","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1185\/03007995.2012.657302","article-title":"Daily and intermittent rosuvastatin 5mg therapy in statin intolerant patients: an observational study","volume":"28","author":"Meek","year":"2012","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.toxlet.2016.10.017_bib0095","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1136\/jcp.2004.015958","article-title":"Statin precipitated lactic acidosis","volume":"57","author":"Neale","year":"2004","journal-title":"J. Clin. Pathol."},{"key":"10.1016\/j.toxlet.2016.10.017_bib0100","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1016\/j.bcp.2003.08.011","article-title":"Comparing myotoxic effects of squalene synthase inhibitor, T-91485, and 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors in human myocytes","volume":"66","author":"Nishimoto","year":"2003","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.toxlet.2016.10.017_bib0105","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.cellsig.2007.07.010","article-title":"PKB and the mitochondria: aKTing on apoptosis","volume":"20","author":"Parcellier","year":"2008","journal-title":"Cell. Signal."},{"key":"10.1016\/j.toxlet.2016.10.017_bib0110","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1097\/JES.0b013e31826c169e","article-title":"Effect of statins on skeletal muscle: exercise, myopathy, and muscle outcomes","volume":"40","author":"Parker","year":"2012","journal-title":"Exerc. Sport Sci. Rev."},{"key":"10.1016\/j.toxlet.2016.10.017_bib0115","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.ijcard.2011.07.048","article-title":"Managing the underestimated risk of statin-associated myopathy","volume":"159","author":"Rallidis","year":"2012","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.toxlet.2016.10.017_bib0120","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1038\/bjp.2008.192","article-title":"Involvement of organic anion transporting polypeptides in the toxicity of hydrophilic pravastatin and lipophilic fluvastatin in rat skeletal myofibres","volume":"154","author":"Sakamoto","year":"2008","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.toxlet.2016.10.017_bib0125","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.ejim.2012.01.004","article-title":"Statin induced myotoxicity","volume":"23","author":"Sathasivam","year":"2012","journal-title":"Eur. J. Intern. Med."},{"key":"10.1016\/j.toxlet.2016.10.017_bib0130","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1254\/jphs.08017FP","article-title":"Effects of rosuvastatin and pitavastatin on ischemia-induced myocardial stunning in dogs","volume":"106","author":"Satoh","year":"2008","journal-title":"J. Pharmacol. Sci."},{"key":"10.1016\/j.toxlet.2016.10.017_bib0135","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13041-016-0191-9","article-title":"Age-related changes in behavior in C57BL\/6J mice from young adulthood to middle age","volume":"9","author":"Shoji","year":"2016","journal-title":"Mol. brain"},{"key":"10.1016\/j.toxlet.2016.10.017_bib0140","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1080\/00498250802585539","article-title":"Statin-induced myopathy in the rat: relationship between systemic exposure, muscle exposure and myopathy","volume":"39","author":"Sidaway","year":"2009","journal-title":"Xenobiotica"},{"key":"10.1016\/j.toxlet.2016.10.017_bib0145","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1111\/j.1365-2125.2003.02044.x","article-title":"Professional athletes suffering from familial hypercholesterolaemia rarely tolerate statin treatment because of muscular problems","volume":"57","author":"Sinzinger","year":"2004","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.toxlet.2016.10.017_bib0150","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.phrs.2014.03.002","article-title":"The pharmacology of statins","volume":"88","author":"Sirtori","year":"2014","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.toxlet.2016.10.017_bib0155","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1016\/j.amjcard.2007.06.029","article-title":"Long-term efficacy and safety of rosuvastatin 40mg in patients with severe hypercholesterolemia","volume":"100","author":"Stein","year":"2007","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.toxlet.2016.10.017_bib0160","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.jns.2012.12.023","article-title":"Decreased skeletal muscle mitochondrial DNA in patients with statin-induced myopathy","volume":"325","author":"Stringer","year":"2013","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.toxlet.2016.10.017_bib0165","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1093\/eurheartj\/ehv043","article-title":"Statin-associated muscle symptoms: impact on statin therapy\u2014European Atherosclerosis society consensus panel statement on assessment, aetiology and management","volume":"36","author":"Stroes","year":"2015","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.toxlet.2016.10.017_bib0170","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/S0140-6736(08)61240-4","article-title":"Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised double-blind, placebo-controlled trial","volume":"372","author":"Tavazzi","year":"2008","journal-title":"Lancet (London England)"},{"key":"10.1016\/j.toxlet.2016.10.017_bib0175","doi-asserted-by":"crossref","first-page":"4037","DOI":"10.1096\/fj.11-184218","article-title":"Effects of myosin heavy chain (MHC) plasticity induced by HMGCoA-reductase inhibition on skeletal muscle functions","volume":"25","author":"Trapani","year":"2011","journal-title":"FASEB J."},{"key":"10.1016\/j.toxlet.2016.10.017_bib0180","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S0140-6736(05)67394-1","article-title":"Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins","volume":"366","author":"Trialists","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.toxlet.2016.10.017_bib0185","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/nbt1387","article-title":"Large-scale chemical dissection of mitochondrial function","volume":"26","author":"Wagner","year":"2008","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.toxlet.2016.10.017_bib0190","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/j.1365-2710.2009.01085.x","article-title":"A systematic review and meta-analysis on the therapeutic equivalence of statins","volume":"35","author":"Weng","year":"2010","journal-title":"J. Clin. Pharm. Ther."},{"key":"10.1016\/j.toxlet.2016.10.017_bib0195","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1080\/01926230590908213","article-title":"Statin-induced muscle necrosis in the rat: distribution, development, and fibre selectivity","volume":"33","author":"Westwood","year":"2005","journal-title":"Toxicol. Pathol."},{"key":"10.1016\/j.toxlet.2016.10.017_bib0200","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1177\/0192623307311412","article-title":"Rosuvastatin: characterization of induced myopathy in the rat","volume":"36","author":"Westwood","year":"2008","journal-title":"Toxicol. Pathol."},{"key":"10.1016\/j.toxlet.2016.10.017_bib0205","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1253\/circj.CJ-10-0110","article-title":"Pleiotropic effects of statins: basic research and clinical perspectives","volume":"74","author":"Zhou","year":"2010","journal-title":"Circ. J."}],"container-title":["Toxicology Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S037842741633291X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S037842741633291X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,26]],"date-time":"2020-09-26T22:28:26Z","timestamp":1601159306000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S037842741633291X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":41,"alternative-id":["S037842741633291X"],"URL":"https:\/\/doi.org\/10.1016\/j.toxlet.2016.10.017","relation":{},"ISSN":["0378-4274"],"issn-type":[{"value":"0378-4274","type":"print"}],"subject":[],"published":{"date-parts":[[2017,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rosuvastatin safety: An experimental study of myotoxic effects and mitochondrial alterations in rats","name":"articletitle","label":"Article Title"},{"value":"Toxicology Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.toxlet.2016.10.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}